Retatrutide in Type 2 Diabetes and Heart Disease: TRIUMPH-2 and TRIUMPH-3 Results
TRIUMPH-2 and TRIUMPH-3 tested retatrutide in people with type 2 diabetes and with heart disease. What the 80-week results showed, and why heart protection is unproven.

Important: investigational medicine notice. Retatrutide has not received marketing authorisation from the MHRA and cannot be legally prescribed, dispensed or sold in the UK outside of an authorised clinical trial. This article is for information only. It is not medical advice and is not a recommendation to seek or use retatrutide. If you are considering weight-management medication, speak to your GP or a regulated UK prescriber about MHRA-approved options.
Retatrutide in Type 2 Diabetes and Heart Disease: TRIUMPH-2 and TRIUMPH-3 Results
Most headline figures for retatrutide come from people without diabetes. Two phase 3 trials, TRIUMPH-2 and TRIUMPH-3, tested it in groups that are often harder to treat: adults with type 2 diabetes, and adults with established cardiovascular disease. Eli Lilly announced topline results for both on 23 July 2026, and TRIUMPH-2 was published in The Lancet on 29 September 2026.
What the evidence supports is that retatrutide reduced weight substantially in both groups, and lowered blood glucose in people with diabetes. What TRIUMPH-3 did not show is that retatrutide reduces heart attacks or strokes. That question belongs to a separate trial that has not yet reported.
The short answer
- TRIUMPH-2 (type 2 diabetes): average weight loss of 20.8% at 80 weeks on 12 mg, against 4.0% on placebo, with HbA1c falling by up to 1.6 percentage points.
- TRIUMPH-3 (cardiovascular disease): average weight loss of 22.6% on 12 mg, against 3.2% on placebo.
- Neither trial was designed to prove fewer cardiovascular events.
- Retatrutide remains unlicensed in the UK.
TRIUMPH-2: obesity with type 2 diabetes
TRIUMPH-2 enrolled 1,152 adults with type 2 diabetes and a body mass index (BMI) of 27 or above, who received retatrutide 4 mg, 9 mg or 12 mg, or placebo, for 80 weeks. Average HbA1c at the start was 7.7%. HbA1c is a blood test that reflects average glucose levels over the previous two to three months.
The 12 mg dose produced average weight loss of 20.8%, against 4.0% on placebo, and HbA1c fell by up to 1.6 percentage points, compared with 0.2 on placebo. Dysaesthesia, an altered skin sensation, was reported in 4.5% to 7.3% of people on retatrutide, against 0.7% on placebo.
The weight loss is smaller than in TRIUMPH-1, which excluded people with diabetes and reported 28.3% at the same dose. The same pattern is seen with licensed medicines: people with type 2 diabetes tend to lose less weight than people without it on Wegovy (semaglutide) and Mounjaro (tirzepatide).
TRIUMPH-3: obesity with established cardiovascular disease
TRIUMPH-3 enrolled 1,949 adults with a BMI of 35 or above and established cardiovascular disease, such as a previous heart attack or stroke, with or without diabetes. Participants received 9 mg, 12 mg or placebo for 80 weeks. Average weight loss was 21.6% on 9 mg and 22.6% on 12 mg, against 3.2% on placebo.
Lilly also reported major cardiovascular events. There were 44 events across the two retatrutide groups and 52 on placebo, a hazard ratio of 0.82 with a 95% confidence interval of 0.55 to 1.22. Because that range crosses 1, the trial cannot show that retatrutide lowered the risk. Lilly said events were less frequent than expected in all groups, which leaves the trial underpowered for this question.
In practice, this means TRIUMPH-3 is a weight-loss trial in people with heart disease, not proof of heart protection. By contrast, Wegovy has an MHRA licence to reduce cardiovascular risk based on the SELECT outcomes trial. The dedicated retatrutide study, TRIUMPH-Outcomes, is ongoing.
What remains unknown
- Heart and kidney outcomes. These await TRIUMPH-Outcomes.
- Full TRIUMPH-3 data. Much of what is known comes from Lilly's topline release.
- Long-term safety beyond 80 weeks, including the significance of dysaesthesia.
- Direct comparisons with licensed medicines, as neither trial included one.
For a fuller safety picture from earlier trials, see our article on retatrutide side effects and safety.
What this means for UK patients
As of October 2026, retatrutide has no MHRA marketing authorisation, and Lilly plans to submit it to the US Food and Drug Administration in the first quarter of 2027. People with type 2 diabetes or heart disease who want to discuss weight-management treatment should speak to their GP, diabetes team or cardiologist about licensed options. Our pillar guide to weight loss medication in the UK sets out what is currently approved.
The bottom line
TRIUMPH-2 and TRIUMPH-3 show that retatrutide's weight-loss effect extends to people with type 2 diabetes and established heart disease, with average losses of around 21% to 23% at the highest dose. TRIUMPH-3 did not demonstrate fewer cardiovascular events, and that remains unproven. Anyone with diabetes or heart disease considering weight-loss medication should speak to their GP or a regulated UK prescriber about MHRA-approved options.
Sources and further reading
- Bellido V, et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet. 2026 (published online 29 September 2026).
- Eli Lilly and Company: Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C (topline press release, 23 July 2026)
- ClinicalTrials.gov: A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3), NCT05882045
- ClinicalTrials.gov: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes), NCT06383390
Related reading from the Health Hub
- What is retatrutide? A clinical overview
- How retatrutide works
- Mounjaro explained: how it differs from other weight loss medications
Always speak to your GP or a regulated UK prescriber before starting, stopping or changing any medication. This article is for general information only and does not replace individual medical advice.
Get weekly weight loss tips
Join our newsletter for provider updates, expert guidance, and exclusive offers — no spam.
Subscribe free